The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit

<i>Background and Objectives</i>: N-acetylcysteine (NAC) is a mucolytic agent used to prevent ventilator-associated pneumonia in intensive care units. This study aimed to evaluate the oral bioavailability of NAC in critically ill patients with pneumonia, isolated acute brain injury and a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kersti Teder, Liivi Maddison, Hiie Soeorg, Andres Meos, Juri Karjagin
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	N-acetylcysteine pharmacokinetics bioavailability infection prevention pneumonia Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/fcbf4b7f10cc4fa5ba0745f2073af60d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:fcbf4b7f10cc4fa5ba0745f2073af60d
record_format	dspace
spelling	oai:doaj.org-article:fcbf4b7f10cc4fa5ba0745f2073af60d2021-11-25T18:18:41ZThe Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit10.3390/medicina571112181648-91441010-660Xhttps://doaj.org/article/fcbf4b7f10cc4fa5ba0745f2073af60d2021-11-01T00:00:00Zhttps://www.mdpi.com/1648-9144/57/11/1218https://doaj.org/toc/1010-660Xhttps://doaj.org/toc/1648-9144<i>Background and Objectives</i>: N-acetylcysteine (NAC) is a mucolytic agent used to prevent ventilator-associated pneumonia in intensive care units. This study aimed to evaluate the oral bioavailability of NAC in critically ill patients with pneumonia, isolated acute brain injury and abdominal sepsis. <i>Materials and Methods</i>: This quantitative and descriptive study compared NAC’s pharmacokinetics after intravenous and enteral administration. 600 mg of NAC was administered in both ways, and the blood levels for NAC were measured. <i>Results</i>: 18 patients with pneumonia, 19 patients with brain injury and 17 patients with abdominal sepsis were included in the population pharmacokinetic modelling. A three-compartmental model without lag-time provided the best fit to the data. Oral bioavailability was estimated as 11.6% (95% confidence interval 6.3–16.9%), similar to bioavailability in healthy volunteers and patients with chronic pulmonary diseases. <i>Conclusions</i>: The bioavailability of enteral NAC of ICU patients with different diseases is similar to the published data on healthy volunteers.Kersti TederLiivi MaddisonHiie SoeorgAndres MeosJuri KarjaginMDPI AGarticleN-acetylcysteinepharmacokineticsbioavailabilityinfection preventionpneumoniaMedicine (General)R5-920ENMedicina, Vol 57, Iss 1218, p 1218 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	N-acetylcysteine pharmacokinetics bioavailability infection prevention pneumonia Medicine (General) R5-920
spellingShingle	N-acetylcysteine pharmacokinetics bioavailability infection prevention pneumonia Medicine (General) R5-920 Kersti Teder Liivi Maddison Hiie Soeorg Andres Meos Juri Karjagin The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit
description	<i>Background and Objectives</i>: N-acetylcysteine (NAC) is a mucolytic agent used to prevent ventilator-associated pneumonia in intensive care units. This study aimed to evaluate the oral bioavailability of NAC in critically ill patients with pneumonia, isolated acute brain injury and abdominal sepsis. <i>Materials and Methods</i>: This quantitative and descriptive study compared NAC’s pharmacokinetics after intravenous and enteral administration. 600 mg of NAC was administered in both ways, and the blood levels for NAC were measured. <i>Results</i>: 18 patients with pneumonia, 19 patients with brain injury and 17 patients with abdominal sepsis were included in the population pharmacokinetic modelling. A three-compartmental model without lag-time provided the best fit to the data. Oral bioavailability was estimated as 11.6% (95% confidence interval 6.3–16.9%), similar to bioavailability in healthy volunteers and patients with chronic pulmonary diseases. <i>Conclusions</i>: The bioavailability of enteral NAC of ICU patients with different diseases is similar to the published data on healthy volunteers.
format	article
author	Kersti Teder Liivi Maddison Hiie Soeorg Andres Meos Juri Karjagin
author_facet	Kersti Teder Liivi Maddison Hiie Soeorg Andres Meos Juri Karjagin
author_sort	Kersti Teder
title	The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit
title_short	The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit
title_full	The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit
title_fullStr	The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit
title_full_unstemmed	The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit
title_sort	pharmacokinetic profile and bioavailability of enteral n-acetylcysteine in intensive care unit
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/fcbf4b7f10cc4fa5ba0745f2073af60d
work_keys_str_mv	AT kerstiteder thepharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT liivimaddison thepharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT hiiesoeorg thepharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT andresmeos thepharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT jurikarjagin thepharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT kerstiteder pharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT liivimaddison pharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT hiiesoeorg pharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT andresmeos pharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit AT jurikarjagin pharmacokineticprofileandbioavailabilityofenteralnacetylcysteineinintensivecareunit
_version_	1718411357458530304

The Pharmacokinetic Profile and Bioavailability of Enteral N-Acetylcysteine in Intensive Care Unit

Ejemplares similares